5:17 PM
 | 
Mar 24, 2014
 |  BC Extra  |  Company News

Japan approves at least six new drugs

Japan's Ministry of Health, Labor and Welfare (MHLW) approved at least six new drugs on Monday, including Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) to treat castration-resistant prostate cancer (CRPC). The Japanese approval triggers a $15 million milestone payment from the pharma to partner Medivation...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >